Faron Pharmaceuticals Oy (LON:FARN) Reaches New 1-Year Low – Should You Sell?

Faron Pharmaceuticals Oy (LON:FARN)’s share price hit a new 52-week low on Wednesday . The company traded as low as GBX 53.50 and last traded at GBX 57.80, with a volume of 1874604 shares. The stock had previously closed at GBX 67.

Faron Pharmaceuticals Oy Stock Down 13.7%

The firm’s 50 day moving average price is GBX 173.45 and its two-hundred day moving average price is GBX 186.65. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The firm has a market capitalization of £66.13 million, a PE ratio of -2.14 and a beta of 0.36.

Insider Activity at Faron Pharmaceuticals Oy

In other news, insider Jurriaan Dekkers sold 4,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of GBX 182, for a total value of £7,280. Insiders own 4.05% of the company’s stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.